Your Article Summary
See Latest ArticlesAllos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status
Allos Therapeutics, 05/27/09
Allos Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The Company also announced that the FDA has granted the NDA priority review status and established a Prescription Drug User Fee Act date of September 2009 for a decision regarding approval of the NDA. Priority review designation is assigned to drugs that have the potential to provide a significant improvement compared to marketed products or provide a safe and effective therapy where no satisfactory therapy exists.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Archives of Neurology, 11/23/09
Medtronic Receives FDA Warning Letter Following Inspection of Its Mounds View, Minn. Facility
Medtronic, 11/19/09
Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin
Current Medical Research and Opinion, 11/17/09